TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hutchmed
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

HUTCHMED launched a global Phase I/IIa clinical trial for HMPL-A251, a novel antibody-targeted therapy conjugate (ATTC) designed to treat HER2-expressing solid tumors with potentially improved safety and efficacy.

Insights
HCM   positive

Company is advancing innovative cancer treatment platform with first-in-human trial of a novel therapeutic approach, demonstrating technological innovation and potential clinical progress